Explore

Rapid ReadRapid Read
Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies, a company focused on developing naturally modified mRNA medicines, has secured $47 million in financing. This funding includes a Series A round led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The investment will support the advancement and scaling of Sensible's integrated mRNA technology, specifically its VECTOR™ platform. This platform aims to overcome limitations of conventional synthetic mRNA production by using living cells to produce naturally modified mRNA. The company's approach is designed to reduce immunogenicity, achieve high protein expression, and avoid double-stranded RNA (dsRNA) contamination, a common issue with synthetic mRNA. Sensible Biotechnologies plans to use this financing to scale up its VECTOR platform, expand its AI-enabled mRNA design and high-throughput screening capabilities, and develop clinical-grade manufacturing capabilities.
TrendlineTrendline
ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance
TrendlineTrendline
Sidley Austin LLP Advises GE HealthCare in $945 Million Acquisition of SOFIE Biosciences

Sidley Austin LLP Advises GE HealthCare in $945 Million Acquisition of SOFIE Biosciences

Sidley Austin LLP Advises GE HealthCare in $945 Million Acquisition of SOFIE Biosciences
Rapid ReadRapid Read
AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

Artificial Intelligence (AI)-enabled tools are fundamentally changing how clinical trial feasibility is conducted, shifting it from a retrospective validation step to an ongoing, iterative part of protocol development. Traditionally, feasibility studies were performed late in the process, after a protocol was largely finalized, leading to delays and costly amendments if assumptions about cohort sizes, outcome rates, or eligibility criteria proved incorrect. AI tools, such as those offered by TriNetX, now allow study teams to evaluate assumptions against real-world data (RWD) continuously as criteria are being set. This is made possible by natural language interfaces that enable users to enter eligibility criteria in plain language, which the system then translates into clinical code sets to generate patient counts instantly. For example, adjusting a single BMI exclusion criterion in a type 2 diabetes query can change the cohort size by thousands of patients in real-time, providing immediate visual feedback...
Rapid ReadRapid Read
AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...
TrendlineTrendline
RoslinCT Awarded £7.25 Million Scottish Enterprise Grant to Advance Digital Cell Therapy Manufacturing

RoslinCT Awarded £7.25 Million Scottish Enterprise Grant to Advance Digital Cell Therapy Manufacturing

RoslinCT Awarded £7.25 Million Scottish Enterprise Grant to Advance Digital Cell Therapy Manufacturing
TrendlineTrendline
CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases

CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases

CSL Licenses Anti-Claudin-1 Antibody from Alentis Therapeutics in $1.55 Billion Deal for Kidney and Liver Diseases
TrendlineTrendline
AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment
ReutersReuters
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US investment plan, a move expected to expand its workforce in the state by more than 50% in the coming years.
Rapid ReadRapid Read
HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...
TrendlineTrendline
Multiply Labs Secures $75 Million to Automate Drug Manufacturing

Multiply Labs Secures $75 Million to Automate Drug Manufacturing

Multiply Labs Secures $75 Million to Automate Drug Manufacturing
TrendlineTrendline
Bora Biologics and Protect Animal Health Partner for Antibody-Based Animal Health Products

Bora Biologics and Protect Animal Health Partner for Antibody-Based Animal Health Products

Bora Biologics and Protect Animal Health Partner for Antibody-Based Animal Health Products